Norgine Ventures Investment Team
Peter Stein is the Chairman and Chief Executive and principal shareholder of Norgine, an independent, specialty pharmaceutical company with operations throughout Europe. In 2012 Peter founded Norgine Ventures. Prior to joining Norgine in 1987, Peter was a co-founder and Vice President of Invitron Corporation, a contract biomanufacturer formed as a spin-off from the Monsanto Company. He started his pharmaceutical career with Centocor.
Peter holds BA and MA degrees in Chemistry from Harvard University and an MBA from Stanford University.
Peter Martin joined Norgine in 2004. Peter has worked in a variety of sales, marketing, research and development and general management roles in the pharmaceutical industry in Europe and the US for the past thirty-six years. He has always been keenly interested in the interface between the healthcare industry and the individual patient.
Peter has an MA in Chemistry from Oxford University and an MBA from the Open University.
Julien Michaux joined Norgine Ventures from Lazard where as a member of the Healthcare M&A team he advised many European and US clients on merger and acquisition transactions. Julien joined Lazard in 2005 from J&J Pharmaceuticals where he worked as part of the M&A team. Julien has 11 years of experience in the Healthcare industry. He started his career with Procter & Gamble.
Julien holds an MS in Engineering from ICAM in France and an MBA from the Anderson School at UCLA.
Alex joined Norgine Ventures in 2013 from AlixPartners, a global consulting firm, where he worked in their Financial Advisory Services team. Prior to this, he worked for over two years in the Investment Management industry with Allianz Global Investors and BlackRock. Alex started his career at Deloitte in Australia, where he spent over three years.
Alex is a qualified Chartered Accountant (CA) from Australia and holds degrees in Commerce and Banking & International Business from Flinders University. He has also undertaken the Private Equity and Venture Capital course at Harvard Business School, Boston, USA.
Moritz joined Norgine Ventures in 2016. He started his finance career as an analyst on the structured products team at Schroders Private Bank in London, before joining the investment team of a family office in New York. Moritz holds a PhD and MSc degree in Physics from Imperial College London and a BSc from The University of Edinburgh.
Kristine joined Norgine Ventures in 2016 from the Lazard Healthcare M&A team. Kristine holds a BSc Hons in Cell Biology from the University of St. Andrews.